EXEL Exelixis, Inc.

65.83USD-3.60%Mkt Cap: 16.06B USDP/E: 19.71

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatme…

Institutional holders20 on file

Key Statistics

Company
Market Cap16.06B USD
Enterprise Value15.33B USD
Revenue (TTM)2.50B USD
Gross Profit2.24B USD
Net Income (TTM)782.57M USD
Revenue/Share9.77 USD
Last Price65.83 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)19.71
P/E (Forward)15.40
PEG2.56
EV/EBITDA14.86
EV/Revenue6.14
P/S6.43
P/B8.78
EPS (TTM)3.34 USD
EPS (Forward)4.27 USD
52W Range
39.7177% of range73.69
52W High73.69 USD
52W Low39.71 USD
Profitability
Gross Margin96.39%
Oper. Margin40.21%
EBITDA Margin41.33%
Profit Margin33.73%
ROE36.21%
ROA27.51%
ROIC58.20%
ROCE36.60%
Growth
Revenue Growth10.20%
Earnings Growth23.20%
Cash Flow & Leverage
Operating CF884.27M USD
CapEx (TTM)39.93M USD
FCF Margin30.42%
FCF Yield4.73%
Net Debt-729.82M USD
Net Debt/EBITDA-0.71
Net Debt/FCF-0.96
Balance Sheet
Debt/Equity0.08
Current Ratio3.21
Quick Ratio2.99
Book Value/Sh7.50 USD
Cash/Share3.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)61.36 USD
Upside (mean)-6.8%
Target Range41.00 USD – 78.00 USD
41.00-6.8% to mean78.00
# Analysts14
Ownership
Shares Out.244.01M
Float209.78M
Insiders1.87%
Institutions105.19%
Short Interest
Short Ratio10.8d
Short % Float14.42%
Short % Out.10.49%
Shares Short25.59M
Short (prev mo.)28.18M
Technical
SMA 5062.86 (+4.7%)
SMA 20052.63 (+25.1%)
Beta0.42
S&P 52W Chg12.00%
Avg Vol (30d)2.65M
Avg Vol (10d)2.95M
Technical Indicators
RSI (14)46.9
MACD1.4044
MACD Signal2.1657
MACD Hist.-0.7613
BB Upper73.52 USD
BB Middle68.60 USD
BB Lower63.67 USD
BB Width14.36%
ATR (14)2.232 USD
Vol Ratio (20d)1.00x

About Exelixis (NASDAQ: EXEL)

›

Exelixis (NASDAQ: EXEL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,077 employees.

The shares were at 65.83 USD on 19 November 2026, up 61.3% over 52 weeks. Its 52-week range is 39.71 USD to 73.69 USD: the price is 10.7% below the high and 65.8% above the low.

At a market capitalisation of 16.06B USD, it trades at 19.7 times trailing earnings and 15.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.5, a discount of 43% for EXEL.

Exelixis reports return on equity of 36.2%, an operating margin of 40.2% and revenue up 10.2% year over year.

It holds more cash than debt, a net cash position of 729.82M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 61.36 USD is 6.8% below the current price. The next earnings report is expected on 9 February 2027.